This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aapro, M. S. Search for Related Content PubMed PubMed Citation Articles by Aapro, M. S.

Neoadjuvant Therapy in Breast Cancer: Can We Define Its Role?

Clinique de Genolier, Genolier, Switzerland

Correspondence: Matti S. Aapro, M.D., Clinique de Genolier, 1 Route du Muids, Genolier CH-1272, Switzerland. Telephone: 22-366-9136; Fax: 41-22-366-9131; e-mail to:aapro{at}cdg.ch

It remains unclear whether neoadjuvant therapy increases disease-free survival when compared with an approach in which chemotherapy is delayed until after surgery. However, the current rationale for neoadjuvant therapy is based on its usefulness in quickly evaluating the likely benefit of new approaches to treatment and tailoring therapy to the biological characteristics of the individual tumor. In the primary therapy of breast cancer, the Aberdeen study shows that patients unresponsive to an anthracycline-based neoadjuvant regimen may achieve a response when switched to docetaxel. Further, patients with an initial clinical response to CVAP were more likely to show a pathological complete response (pCR) at final assessment when four cycles of CVAP were followed by four of docetaxel than when CVAP was maintained for eight cycles (pCR rate 34% versus 16%). Early data suggest that this difference translates into significantly lengthened progression-free survival. As in other disease settings, it may be possible to devise nonanthracycline-containing neoadjuvant regimens which are at least as effective as those in current use.

Key Words. Neoadjuvant breast cancer • Doxorubicin • Cyclophosphamide • Docetaxel • Cisplatin

This article has been cited by other articles:

				A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions Oncologist, November 1, 2008; 13(11): 1137 - 1148. [Abstract] [Full Text] [PDF]

				M. Dadiani, R. Margalit, N. Sela, and H. Degani High-Resolution Magnetic Resonance Imaging of Disparities in the Transcapillary Transfer Rates in Orthotopically Inoculated Invasive Breast Tumors Cancer Res., May 1, 2004; 64(9): 3155 - 3161. [Abstract] [Full Text] [PDF]

				S. C. A. Michel, T. M. Keller, J. M. Frohlich, D. Fink, R. Caduff, B. Seifert, B. Marincek, and R. A. Kubik-Huch Preoperative Breast Cancer Staging: MR Imaging of the Axilla with Ultrasmall Superparamagnetic Iron Oxide Enhancement Radiology, November 1, 2002; 225(2): 527 - 536. [Abstract] [Full Text] [PDF]

				M. S. Aapro Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001 Oncologist, August 1, 2001; 6(4): 376 - 385. [Abstract] [Full Text] [PDF]